All In Biotech

Drug Trial Radar · NCT06308653

Psilocybin for Major Depressive Disorder (MDD)

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

238

Actual

Start

Mar 13, 2024

Primary completion

Jan 5, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Usona InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period.

Conditions

  • Depressive Disorder, Major

Interventions

  • Psilocybin 25 mgDrug

    The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.

  • Inactive PlaceboDrug

    The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.

  • Psilocybin 5 mgDrug

    The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.

  • Psychosocial SupportBehavioral

    Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline to Trial Day 43Time frame: From Trial Baseline to Trial Day 43

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Clinical Research Unit

    Birmingham, Alabama

  • Preferred Research Partners-NWA, LLC

    Fayetteville, Arkansas

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Kadima Neuropsychiatry Institute

    La Jolla, California

  • West LA VA Medical Center - Mental Health Department

    Los Angeles, California

  • Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners

    Santa Monica, California

  • Psychedelic Science Institute

    Santa Monica, California

  • Mountain View Clinical Research

    Denver, Colorado

  • Connecticut Mental Health Center, Yale University

    New Haven, Connecticut

  • Clinical Neuroscience Solutions Inc.

    Jacksonville, Florida

  • Innovative Clinical Research, Inc.

    Lauderhill, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Emory University

    Atlanta, Georgia

  • CenExel iResearch, LLC

    Decatur, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research

    Baltimore, Maryland

  • Sunstone Medical PC

    Rockville, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • VA Nebraska Western Iowa Health Care System

    Omaha, Nebraska

  • Global Medical Institutes, LLC; Princeton Medical Institute

    Princeton, New Jersey

  • University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center

    Albuquerque, New Mexico

  • NYU Clinical & Translational Science Institute

    New York, New York

  • Bronx Veterans Research Foundation at the James J. Peters VAMC

    The Bronx, New York

  • AIM Trials, LLC

    Plano, Texas

  • Clinical Trials of Texas, LLC

    San Antonio, Texas

  • Cedar Clinical Research

    Draper, Utah

  • Cedar Clinical Research, Inc.

    Murray, Utah

  • Seattle Neuropsychiatric Treatment Center

    Bellevue, Washington

  • VA Portland Health Care System

    Vancouver, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.